Moneygram CEO Talks...
Health Care: Health Services
Trius Therapeutics Inc. (TSRX: NASDAQ)
$7.60 -0.17 | -2.19%
05/22/13 - 04:00 PM ET
895.28K / 876.70K
Vol / Avg. Vol:7.80 / 7.77
Open / Prev. Close:7.51 - 7.90
Today's Range:4.41 - 8.50
52 Wk Range:62.55%
Performance YTD:TheStreet Rating:
Portfolios with TSRX
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- UserAshley
- ContributorUnder-$10 Setting Up To Tra...
- ContributorStocks Under-$10 Moving Hig...
Latest TSRX Headlines from TheStreet
- Cubist, Optimer, Trius: Antibiotic Deal Making On Tap 05.22.13 | 07:05 am
- Trius Announces Notice Of Allowance Of U.S. Patent Application Related To Tedizolid Phosphate Combination With Daptomycin 05.13.13 | 08:05 am
- Trius Therapeutics Reports First Quarter 2013 Financial Results 05.07.13 | 04:05 pm
- Cramer's Top Stock Picks: BRK.B FB TSRX 05.04.13 | 06:05 am
- Cramer's 'Mad Money' Recap: Next Week's Game Plan (Correct) 05.03.13 | 07:05 pm
- Trius Therapeutics Presents Clinical Data On Experimental Antibiotic Tedizolid At ECCMID Meeting 04.29.13 | 08:04 am
- Trius Therapeutics To Present Experimental Antibiotic Study Results At ECCMID Meeting 04.23.13 | 08:04 am
- Trius Appoints Seth Fischer To Its Board Of Directors 04.03.13 | 04:04 pm
- Trius To Present At Future Leaders Conference 04.02.13 | 04:04 pm
- Trius Announces Positive Results From ESTABLISH 2 Study Of Tedizolid In Severe Skin Infections 03.25.13 | 07:03 am
Press Releases for TSRX
- Trius Announces Issuance Of Key U.S. Patent For Torezolid Phosphate - PR Newswire 10.25.10 | 04:10 pm
- Trius To Present At San Diego Biotechnology Network Event - PR Newswire 10.22.10 | 04:10 pm
- Trius To Present At 7th Anti-Infectives Partnering And Deal-Making Summit - PR Newswire 10.06.10 | 04:10 pm
- Trius To Participate In Antibiotics Panel Discussion At Citi's 5th Annual Biotech Day - PR Newswire 10.04.10 | 08:10 am
- Trius Reports New Findings On Mechanisms Of Antibiotic Resistance In MRSA - PR Newswire 09.13.10 | 04:09 pm
- Trius To Present At The Stifel Nicolaus Healthcare Conference - PR Newswire 09.13.10 | 08:09 am
- Trius Therapeutics To Present Data From Drug Development Programs At ICAAC - PR Newswire 09.07.10 | 04:09 pm
- Trius Therapeutics Initiates Phase 3 Program Of Oral Torezolid Phosphate For The Treatment Of ABSSSI - PR Newswire 08.30.10 | 08:08 am
Partner Headlines for TSRX
- Oppenheimer Reiterates Outperform Rating, $12 PT on Trius Therapeutics on 4Q12 EPS - Benzinga 03.13.13 | 01:03 pm
- Trius Therapeutics: New MSRA Treatment Could Bring Billions In Revenues - Seeking Alpha 03.05.13 | 09:03 am
- Who Is Paying Attention To MRSA? - Seeking Alpha 10.23.12 | 09:10 am
- The Company You Keep Speaks Volumes: Novabay And Trius - Seeking Alpha 10.09.12 | 09:10 am
- Big Pharma Abandons Antibiotics: An Opening For Small Biotech - Seeking Alpha 05.13.12 | 09:05 am
- Trius Therapeutics: Outstanding Potential, Discount Price - Seeking Alpha 01.26.12 | 09:01 am
- Company News for May 27, 2011 - Corporate Summary - Zacks 05.27.11 | 10:05 am
- 16 Small Caps With Cash to Cover 1+ Years of Operating Expenses - Seeking Alpha 04.20.11 | 04:04 am
